Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 12/20 | 0.39 |
| ▸ | CA1 | P00915 | 9/20 | 0.39 |
| ▸ | CA9 | Q16790 | 9/20 | 0.39 |
| ▸ | CA12 | O43570 | 5/20 | 0.39 |
| ▸ | CA6 | P23280 | 3/20 | 0.39 |
| ▸ | CA5A | P35218 | 3/20 | 0.39 |
| ▸ | CA4 | P22748 | 2/20 | 0.39 |
| ▸ | CA7 | P43166 | 2/20 | 0.39 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.39 |
| ▸ | STAT3 | P40763 | 1/20 | 0.35 |
| ▸ | ALOX5AP | P20292 | 3/20 | 0.33 |
| ▸ | FEN1 | P39748 | 3/20 | 0.33 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.32 |
| ▸ | LDHA | P00338 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1080972 | 0.72 | CA2 (0.61) | CA2CA1CA9CA12CA6 | |
| SCHEMBL8347239 | 0.70 | CA2 (0.58) | CA2CA1CA9CA12CA6 | |
| SCHEMBL6820364 | 0.67 | CA2 (0.50) | CA2CA1CA9CA12CA6 | |
| SCHEMBL8350056 | 0.67 | CA1 (0.54) | CA2CA1CA9CA12CA6 | |
| SCHEMBL1116406 | 0.66 | CA2 (0.56) | CA2CA1CA9CA12CA6 | |
| SCHEMBL8621773 | 0.66 | PTGS2 (0.48) | CA2CA1CA9CA12CA6 | |
| SCHEMBL48885 | 0.65 | CA2 (0.52) | CA2CA1CA9CA12CA6 | |
| SCHEMBL202947 | 0.65 | CA2 (0.70) | CA2CA1CA9CA12CA6 | |
| Ammonia Solution, Strong SCHEMBL28645552 | 0.65 | CA2 (0.55) | CA2CA1CA9CA12CA6 | |
| SCHEMBL7967712 | 0.64 | CA2 (0.50) | CA2CA1CA9CA12CA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1435956-A2 | THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS | Pharmacia Corporation (US) | 2004-07-14 | — | — | EP | claimed |
| EP-1416940-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND GLUCOSAMINE | Pharmacia Corporation (US) | 2004-05-12 | — | — | EP | claimed |
| WO-2003015797-A1 | COMPOSITIONS FOR THE TREATMENT AND PREVENTION OF PAIN AND INFLAMMATION WITH A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND GLUCOSAMINE | PHARMACIA CORPORATION (US) | 2003-02-27 | — | — | WO | claimed |
| WO-2002078626-A2 | THERAPEUTIC COMBINATIONS FOR CARDIOVASCULAR AND INFLAMMATORY INDICATIONS | PHARMACIA CORPORATION (US) | 2002-10-10 | — | — | WO | claimed |
| WO-1998050075-A1 | COX-2 INHIBITORS IN COMBINATION WITH NMDA-BLOCKERS FOR TREATING PAIN | ALGOS PHARMACEUTICAL CORPORATION (US) | 1998-11-12 | — | — | WO | claimed |
| WO-2018187698-A2 | COMBINATION THERAPIES USING CASPASE-1 DEPENDENT ANTICANCER AGENTS AND PGE2 ANTAGONISTS | TRUSTEES OF TUFTS COLLEGE (US) | 2018-10-11 | — | — | WO | disclosed |
| EP-1691797-A2 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITOR AND PHOSPHODIESTERASE 4 INHIBITOR AND METHOD | Pharmacia Corporation (US) | 2006-08-23 | — | — | EP | disclosed |
| EP-1569640-A4 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | PHARMACIA CORP (US) | 2006-06-21 | — | — | EP | disclosed |
| EP-1575594-A2 | COMBINATION OF REBOXETINE AND A CYCLOOXYGENASE-2 INHIBITOR | Pharmacia Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| EP-1569640-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | Pharmacia Corporation (US) | 2005-09-07 | — | — | EP | disclosed |
| WO-2005041864-A2 | COMBINATION OF CYCLOOXYGENASE-2 INHIBITOR AND PHOSPHODIESTERASE 4 INHIBITOR AND METHOD | PHARMACIA CORPORATION (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005037259-A2 | METHODS AND COMPOSITIONS FOR THE PREVENTION OR TREATMENT OF NEOPLASIA COMPRISING A COX-2 INHIBITOR IN COMBINATION WITH AN EPIDERMAL GROWTH FACTOR RECEPTOR ANTAGONIST | PHARMACIA CORPORATION (US) | 2005-04-28 | — | — | WO | disclosed |
| WO-2004093814-A2 | COMPOSITIONS OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A SODIUM CHANNEL BLOCKER | PHARMACIA CORPORATION (US) | 2004-11-04 | — | — | WO | disclosed |
| EP-1471872-A2 | TREATMENT OF COLDS AND COUGH WITH A COMBINATION OF A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND A COLDS AND COUGH ACTIVE INGREDIENT AND COMPOSITIONS THEREOF | Pharmacia Corporation (US) | 2004-11-03 | — | — | EP | disclosed |
| WO-2004060361-A2 | COMBINATION OF REBOXETINE AND A CYCLOOXYGENASE-2 INHIBITOR | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004060366-A1 | A METHOD FOR THE TREATMENT, PREVENTION, OR INHIBITION OF A CNS DISORDER AND/OR PAIN AND INFLAMMATION USING A COMBINATION OF DULOXETINE, VENLAFAXINE OR ATOMOXETINE AND A CYCLOOXYGENASE-2 SELECTIVE INHIBITOR AND COMPOSITIONS THEREOF | PHARMACIA CORPORATION (US) | 2004-07-22 | — | — | WO | disclosed |
| WO-2004045509-A2 | METHOD OF USING A COX-2 INHIBITOR AND A 5-HT1A RECEPTOR MODULATOR AS A COMBINATION THERAPY | PHARMACIA CORPORATION (US) | 2004-06-03 | — | — | WO | disclosed |
| WO-2003088958-A2 | COMBINATIONS OF COX-2 INHIBITORS AND OTHER AGENTS FOR THE TREATMENT OF PARKINSON’S DISEASE | PHARMACIA CORPORATION (US) | 2003-10-30 | — | — | WO | disclosed |
| WO-2003065988-A2 | A COMBINATION FOR TREATING COLD AND COUGH | PHARMACIA CORPORATION (US) | 2003-08-14 | — | — | WO | disclosed |
| WO-2003059294-A2 | COMBINATIONS OF PEROXISOME PROLIFERATOR-ACTIVATED RECEPTOR-ALPHA AGONISTS AND CYCLOOXYGENASE-2 SELECTIVE INHIBITORS AND THERAPEUTIC USES THEREFOR | PHARMACIA CORPORATION (US) | 2003-07-24 | — | — | WO | disclosed |